An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.
Also called NCT01574326
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 101 participants
- Sponsor
- Genzyme, a Sanofi Company
- Registry
-
NCT01574326 -
2011-002329-23
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, France, Germany, Lithuania, Poland
- Registry status
- Completed
Technical summary
Registry record NCT01574326. Randomized; double masking; primary purpose treatment. Start 2012-05 (registry gives no type); primary completion 2015-06 (actual). Results posted on 2016-07-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease
- Condition
- Hyperphosphatemia
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Sevelamer carbonate
- Lead sponsor
- Genzyme, a Sanofi Company
Record details
- Record id
cardio:ct-nct01574326- Content hash
f3be5b41ed75f72160f6f18e3b03a363cc49acfdcb47522b6ca16592a5850485